|
1
|
Grayson M: Bladder cancer. Nature.
551:S332017. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tuccori M, Filion KB, Yin H, Yu OH, Platt
RW and Azoulay L: Pioglitazone use and risk of bladder cancer:
Population based cohort study. BMJ. 352:i15412016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sato Y, Kondo T, Takagi T, Junpei I and
Tanabe K: Treatment strategy for bladder cancer in patients on
hemodialysis: A clinical review of 28 cases. Int Urol Nephrol.
48:503–509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang GL, Zhang LH, Liu Q, Wang ZL, Duan
XH, Huang YR and Bo JJ: Commentary on ‘A novel treatment strategy
for newly diagnosed high-grade T1 bladder cancer: gemcitabine and
cisplatin adjuvant chemotherapy-A single-institution experience’.
Urol Oncol. 36:346–347. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heidari F, Abbas Zade S, Mir Hosseini SH
and Ghadian A: Metformin for the prevention of bladder cancer
recurrence: Is it effective? Nephrourol Mon. 8:e302612016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parodi A, Traverso P, Kalli F, Conteduca
G, Tardito S, Curto M, Grillo F, Mastracci L, Bernardi C, Nasi G,
et al: Residual tumor micro-foci and overwhelming regulatory T
lymphocyte infiltration are the causes of bladder cancer
recurrence. Oncotarget. 7:6424–6435. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mearini E, Poli G, Cochetti G, Boni A,
Egidi MG and Brancorsini S: Expression of urinary miRNAs targeting
NLRs inflammasomes in bladder cancer. OncoTargets Ther.
10:2665–2673. 2017. View Article : Google Scholar
|
|
9
|
Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu
H, Ye Z and Li LC: Up-regulation of p21(WAF1/CIP1) by miRNAs and
its implications in bladder cancer cells. FEBS Lett. 588:4654–4664.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lan G, Yang L, Xie X, Peng L and Wang Y:
MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in
human bladder cancer. Arch Med Sci. 11:561–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Liang Z, Xu X, Li J, Zhu Y, Meng
S, Li S, Wang S, Xie B, Ji A, et al: miR-148a-3p represses
proliferation and EMT by establishing regulatory circuits between
ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death Dis.
7:e25032016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang Z, Wang X, Xu X, Xie B, Ji A, Meng
S, Li S, Zhu Y, Wu J, Hu Z, et al: MicroRNA-608 inhibits
proliferation of bladder cancer via AKT/FOXO3a signaling pathway.
Mol Cancer. 16:962017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao F, Ge YZ, Zhou LH, Xu LW, Xu Z, Ping
WW, Wang M, Zhou CC, Wu R and Jia RP: Identification of hub miRNA
biomarkers for bladder cancer by weighted gene coexpression network
analysis. OncoTargets Ther. 10:5551–5559. 2017. View Article : Google Scholar
|
|
14
|
Wang Y, Du C, Zhang N, Li M, Liu Y, Zhao
M, Wang F and Luo F: TGF-β1 mediates the effects of aspirin on
colonic tumor cell proliferation and apoptosis. Oncol Lett.
15:5903–5909. 2018.PubMed/NCBI
|
|
15
|
Chen W, Wang J, Liu S, Wang S, Cheng Y,
Zhou W, Duan C and Zhang C: MicroRNA-361-3p suppresses tumor cell
proliferation and metastasis by directly targeting SH2B1 in NSCLC.
J Exp Clin Cancer Res. 35:762016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen Z, Zhang Y, Wang X, Zeng X, Hu Z, Liu
Y, Xie Y, Liang G, Zhu J, Luo H, et al: Novel 3′,5′-diprenylated
chalcones inhibited the proliferation of cancer cells in vitro by
inducing cell apoptosis and arresting cell cycle phase. Eur J Med
Chem. 133:227–239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yano S, Mii S, Tome Y, Hiroshima Y, Uehara
F, Miwa S and Hoffman RM: Abstract A41: Cancer cells invade or
divide, not both. Cancer Res. 73 Suppl 3:A412013. View Article : Google Scholar
|
|
18
|
Baumgart S, Hölters S, Ohlmann CH, Bohle
R, Stöckle M, Ostenfeld MS, Dyrskjøt L, Junker K and Heinzelmann J:
Exosomes of invasive urothelial carcinoma cells are characterized
by a specific miRNA expression signature. Oncotarget.
8:58278–58291. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen W, Ye L, Wen D and Chen F: MiR-490-5p
inhibits hepatocellular carcinoma cell proliferation, migration and
invasion by directly regulating ROBO1. Pathol Oncol Res. 2:1–9.
2017.
|
|
20
|
Othman N, In LL, Harikrishna JA and Hasima
N: Bcl-xL silencing induces alterations in hsa-miR-608 expression
and subsequent cell death in A549 and SK-LU1 human lung
adenocarcinoma cells. PLoS One. 8:e817352013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lombard A, Mooso B, Libertini S, Lim R,
Costanzo N, Ghosh P and Mudryj M: Abstract 5239: MiR-148a promotes
apoptosis in urothelial cell carcinoma of the bladder cells in part
by targeting DNMT1. Cancer Res. 74 Suppl 19:52392014. View Article : Google Scholar
|
|
22
|
He L, Meng D, Zhang SH, Zhang Y, Deng Z
and Kong LB: microRNA-608 inhibits human hepatocellular carcinoma
cell proliferation via targeting the BET family protein BRD4.
Biochem Biophys Res Commun. 501:1060–1067. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, Chen
H, Mao Y, Lin Y, Luo J, et al: MicroRNA-490-5p inhibits
proliferation of bladder cancer by targeting c-Fos. Biochem Biophys
Res Commun. 441:976–981. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mao LM, Chen YH and Liao ZP: The abnormal
expression of miR-148a in bladder cancer and its clinical
significance. Chin J Health Lab Tech. 15:2143–2145. 2017.(In
Chinese).
|
